Isoniazid preventive treatment: predictors of adverse events and treatment completion

Codecasa, Luigi; Murgia, Nicola; Ferrarese, Maurizio; Delmastro, Monica; Repossi, Alice; Casali, Lucio; Besozzi, Giorgio; Ferrara, Giovanni; Raviglione, Mario

doi:10.5588/ijtld.12.0677

Cited by 24 publications

(38 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 23 publications related to RCTs and 55 related to nonrandomized studies were included. A flow diagram documenting the process of study selection is provided in Figure .…”

Section: Resultsmentioning

confidence: 99%

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

Pease

Hutton

Yazdi

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…A total of 23 publications related to RCTs and 55 related to nonrandomized studies were included. A flow diagram documenting the process of study selection is provided in Figure .…”

Section: Resultsmentioning

confidence: 99%

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

Pease

Hutton

Yazdi

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…During follow-up, AEs were evaluated through patient's self-reporting symptoms (e.g., headache, nausea) and blood tests, generally focused on assessing liver enzyme levels. Based on symptom severity, the patient's general conditions, and lab abnormalities, a drug regimen could be momentarily stopped, definitively stopped, or changed [17].…”

Section: Preventive Treatment Regimens Follow-up and Outcomesmentioning

confidence: 99%

Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy

Villa

Ferrarese

Sotgiu

et al. 2019

JCM

View full text Add to dashboard Cite

To tackle the tuberculosis (TB) epidemic, in 2014 the World Health Organization launched the End TB Strategy, which includes action to prevent latent TB infection (LTBI) reactivation. Available preventive treatments (PT) are based on either isoniazid (INH) alone or rifampicin (RIF)-containing regimens. This study aims to assess and compare PT completion rates, the occurrence of adverse events, and the time of dropout among those receiving INH-alone or RIF-containing regimens at Villa Marelli Institute, Milan, Italy, covering the period from 1992 to 2018. A total of 19,670 subjects, belonging to various risk groups—mainly young (median age of 29 years), foreign-born (73.3%), and males (58.8%)—with presumed LTBI were prescribed PT (79.3% INH-alone and 20.7% RIF-containing regimens). The treatment completion rate was 79.4% on average, with higher rates among those receiving RIF-containing regimens (85.6%) compared to those that were prescribed INH-alone (77.8%) (p < 0.0001). Notably, some of the high-risk groups for progression of LTBI were more likely to complete PT from RIF-containing regimens. These groups included recent TB contact (89.9%, p < 0.0001), healthcare workers (93.5%, p < 0.0001), and homeless people (76.6%, p < 0.0001). Irrespectively of the chosen PT regimen, most of the dropouts occurred between the start of the treatment and the first follow-up visit (14.3%, 15.2% for those on INH-alone vs. 11.1% for those on RIF-containing regimens). Further shortening of the PT regimen is therefore an aim to ensure adherence, even though it might need further efforts to enhance the patient’s attitude towards starting and carrying out PT.

show abstract

“…Preventive treatment was routinely offered to all LTB subjects, with an expected completion rate of about 74% (23,24).…”

Section: Tb Contact Definitionmentioning

confidence: 99%

Yield of tuberculosis contact investigation in a low-incidence country

Borraccino¹,

Migliore

Piccioni³

et al. 2014

Journal of Infection

View full text Add to dashboard Cite

Isoniazid preventive treatment: predictors of adverse events and treatment completion

Abstract: This analysis demonstrates the feasibility and safety of IPT, with determinants of interruption and AEs being predictable and addressable.

Cited by 24 publications

References 21 publications

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy

Yield of tuberculosis contact investigation in a low-incidence country

Contact Info

Product

Resources

About